News
DYAI
1.490
0.00%
0.000
Dyadic International files to sell 3.35M shares for holders
Dyadic International files to sell 3.35M shares for holders Apr. 24, 2024. Dyadic International, Inc. Filed a prospectus related to the proposed resale of about 3. 35M shares of its common stock. This prospectus is not an offer to sell these securities.
Seeking Alpha · 2d ago
DYADIC INTERNATIONAL- FILES PROSPECTUS RELATES TO OFFER AND SALE FROM TIME TO TIME BY SELLING STOCKHOLDERS OF UP TO 3.4 MLN SHARES OF COMMON STOCK
Reuters · 2d ago
Weekly Report: what happened at DYAI last week (0415-0419)?
Weekly Report · 4d ago
Dyadic Intl Inc Del: Statement of changes in beneficial ownership of securities
Press release · 04/16 04:02
Weekly Report: what happened at DYAI last week (0408-0412)?
Weekly Report · 04/15 11:03
Weekly Report: what happened at DYAI last week (0401-0405)?
Weekly Report · 04/08 11:08
Weekly Report: what happened at DYAI last week (0325-0329)?
Weekly Report · 04/01 11:06
Dyadic Intl Inc Del: Annual report
Press release · 03/29 02:23
DYAI Stock Earnings: Dyadic International Misses EPS, Misses Revenue for Q4 2023
Dyadic International reported earnings per share of -8 cents for the fourth quarter of 2023. The company reported revenue of $686,535. This was 14.18% worse than the analyst estimate for revenue. Dyadic International also reported results for the third quarter of 2018.
Investorplace · 03/29 00:53
Dyadic International Inc reports results for the quarter ended in December - Earnings Summary
Dyadic International Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 8 cents per share. Revenue fell 7.7% to $687.00 thousand from a year ago. Dyadic International shares had risen by 1.2% this quarter.
Reuters · 03/28 21:02
Recap: Dyadic International Q4 Earnings
Dyadic International reported its Q4 earnings on March 28, 2024. Dyadic International missed estimated earnings by -33.0%. The company's revenue was down $57 thousand from the same period last year. The company is expected to announce its earnings on April 28.
Benzinga · 03/28 20:50
Dyadic International Announces Key Leadership Changes
TipRanks · 03/28 20:23
Dyadic International GAAP EPS of -$0.24 misses by $0.01, revenue of $2.9M misses by $0.15M
Earnings News Dyadic International GAAP EPS of -$0.24 misses by $0.01, revenue of $2.9M misses by $ 0.15M. Dyadic international, Inc. (DYAI) expected to report its quarterly results on Mar. 28, 2024.
Seeking Alpha · 03/28 20:03
Press Release: Dyadic Reports 2023 Full Year Results and Recent Company Progress
Dyadic Reports 2023 Full Year Results and Recent Company Progress. Dyadic reports positive topline data from First-In-Human Phase 1 trial for DYAI-100 vaccine. Company closed a $6.0 million convertible note in a private placement. Company has entered into several fully funded vaccine and antibody projects.
Dow Jones · 03/28 20:00
Press Release: Dyadic Reports 2023 Full Year -3-
Dyadic's gene expression and protein production platforms are based on the fungus Thermothelomyces heterothallica. Dyadic's lead technology, the C1-cell protein production platform, is used to speed development of biologic vaccines and drugs for the human and animal health markets. The company is building an active pipeline to advance its microbial platform technologies.
Dow Jones · 03/28 20:00
After-Hours Earnings Report for March 28, 2024 : ACHV, ACNT, AREC, AXDX, CPTN, CURV, DARE, DNMR, DYAI, FORA, HSDT, INLX
NASDAQ · 03/28 18:00
Dyadic's Michael Tarnok to step down as Chairman of the board of directors
Dyadic's Michael Tarnok to step down as Chairman of the board of directors. Patrick Lucy has been appointed to succeed him, effective immediately. Dyadic's Barry Buckland announced he is retiring and will not stand for re-election to the board in 2024.
Seeking Alpha · 03/28 12:58
*Dyadic Intl Appoints Joseph Hazelton COO Effective Immediately >DYAI
Dow Jones · 03/28 12:36
*Dyadic Intl Appoints Patrick Lucy Chairman >DYAI
Dow Jones · 03/28 12:35
*Dyadic Intl: Tarnok Will Continue to Serve as a Director Until June>DYAI
Dow Jones · 03/28 12:35
More
Webull provides a variety of real-time DYAI stock news. You can receive the latest news about Dyadic Intl Inc Del through multiple platforms. This information may help you make smarter investment decisions.
About DYAI
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.